ARTICLE | Clinical News

RT002: Ph III started

December 30, 2016 10:07 PM UTC

Revance began a pair of double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of RT002 in about 600 total patients. The trials are part of the company’s Phase...

BCIQ Company Profiles

Revance Therapeutics Inc.